Pharmacia Parecoxib Additional Surgery Studies To Be Initiated Shortly
Executive Summary
Pharmacia's resubmission of its parecoxib NDA will be based on additional trials in orthopedic, gynecologic and coronary artery bypass graft surgery, which the firm plans to complete for a second-half 2003 filing